文献速递肝病

OTUB1通过抑制TRAF6-ASK1信号通路缓解NASH

OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
PubMed 文献 · Hepatology · 2021-12-07

本研究探讨去泛素化酶OTUB1在非酒精性脂肪性肝炎(NASH)中的作用。小鼠实验显示Otub1缺失加重高脂饮食诱导的高胰岛素血症和肝脂肪变,而肝细胞特异性过表达Otub1可显著减轻HFHC饮食诱导的肝脂肪变、炎症和肝纤维化。机制上OTUB1直接结合TRAF6并抑制其K63链接多泛素化,从而抑制ASK1及其下游通路活化。

要点

  • OTUB1缺失加重饮食诱导的高胰岛素血症和肝脂肪变
  • 肝细胞过表达OTUB1减轻脂肪变、炎症和纤维化
  • OTUB1-TRAF6-ASK1轴或为NASH治疗新靶点

核心结论

  • OTUB1是NASH的关键抑制因子,通过抑制TRAF6多泛素化和ASK1活化发挥作用。
  • 靶向OTUB1-TRAF6-ASK1轴可能是NASH有前景的治疗策略。

研究设计与样本

  • 基础实验研究,使用Otub1缺失小鼠和肝细胞特异性Otub1过表达小鼠。
  • 模型包括高脂饮食诱导和高脂高胆固醇(HFHC)饮食诱导。
  • 采用RNA测序分析、免疫印迹分析和免疫沉淀-质谱分析。

主要发现

  • Otub1缺失小鼠在高脂饮食和HFHC饮食下均表现加重的高胰岛素血症和肝脂肪变。
  • 肝细胞特异性Otub1过表达显著减轻HFHC饮食诱导的肝脂肪变、炎症反应和肝纤维化。
  • ASK1被鉴定为OTUB1的关键候选靶点。
  • OTUB1直接结合TRAF6并抑制其赖氨酸63链接多泛素化,从而抑制ASK1及其下游通路活化。

临床怎么用

  • OTUB1-TRAF6-ASK1轴可作为NASH药物开发的潜在靶点。
  • OTUB1表达或活性可能作为NASH干预策略的方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is considered as the hepatic manifestation of the metabolic syndrome, which includes insulin resistance, obesity and hyperlipidemia. NASH is a progressive stage of NAFLD with severe hepatic steatosis, hepatocyte death, inflammation, and fibrosis. Currently, no pharmacological interventions specifically tailored for NASH are approved. Ovarian tumor domain, ubiquitin aldehyde binding 1 (OTUB1), the founding member of deubiquitinases, regulates many metabolism-associated signaling pathways. However, the role of OTUB1 in NASH is unclarified. METHODS AND RESULTS: We demonstrated that mice with Otub1 deficiency exhibited aggravated high-fat diet-induced and high-fat high-cholesterol (HFHC) diet-induced hyperinsulinemia and liver steatosis. Notably, hepatocyte-specific overexpression of Otub1 markedly alleviated HFHC diet-induced hepatic steatosis, inflammatory responses, and liver fibrosis. Mechanistically, we identified apoptosis signal-regulating kinase 1 (ASK1) as a key candidate target of OTUB1 through RNA-sequencing analysis and immunoblot analysis. Through immunoprecipitation-mass spectrometry analysis, we further found that OTUB1 directly bound to tumor necrosis factor receptor-associated factor 6 (TRAF6) and suppressed its lysine 63-linked polyubiquitination, thus inhibiting the activation of ASK1 and its downstream pathway. CONCLUSIONS: OTUB1 is a key suppressor of NASH that inhibits polyubiquitinations of TRAF6 and attenuated TRAF6-mediated ASK1 activation. Targeting the OTUB1-TRAF6-ASK1 axis may be a promising therapeutic strategy for NASH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhang JL, Du BB, Zhang DH, et al. OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways. Hepatology. 2021. PMID: 34591986. doi:10.1002/hep.32179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。